Skip to main content

Schobel Alexander Mark's Form 4/A amendment

Amended

Aquestive Therapeutics, Inc. (AQST) · filed Oct 2, 2024

Accession no.
0001214659-24-017011
Filed
Oct 2, 2024
Trade date
Mar 9, 2024
Filing delay
207 days
Rule 10b5-1 plan
Not checked
Original filed
Mar 12, 2024

This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $129.8K. It was filed 207 days after the trade.

This amendment restates part of 0001214659-24-004389 (filed Mar 12, 2024). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schobel Alexander MarkCIK 0001406836Officer (Chief Innovation/Tech Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 9, 2024Common StockFTax withholdingDisposed−9,645$4.88−$47,067.6980,726Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001214659-24-004389 (filed Mar 12, 2024).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001214659-24-004389
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 8, 2024Common StockSSaleDisposed−25,000$5.19F2−$129,7501,040,371Direct

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F2

Represents the weighted average sales price per share. The shares sold at prices ranging from $5.00 to $5.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 .

Read the full filing on SEC EDGAR (opens in a new tab)